Project/Area Number |
26462597
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Otorhinolaryngology
|
Research Institution | Kanazawa University |
Principal Investigator |
|
Co-Investigator(Renkei-kenkyūsha) |
YOSHIZAKI Tomokazu 金沢大学, 医学系, 教授 (70262582)
MURONO Shigeyuki 福島県立医科大学, 医学部, 教授 (20345622)
KONDO Satoru 金沢大学, 附属病院, 助教 (70436822)
ENDO Kazuhira 金沢大学, 附属病院, 助教 (30547154)
TSUJI Akira 金沢大学, 医学系, 協力研究員 (70632652)
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Keywords | 上咽頭癌 / EBV / EBERs / miR-BARTs / エクソソーム / Argonaute 2 / LMP1 / 前転移ニッチ |
Outline of Final Research Achievements |
EBV-associated oncoprotein, LMP1, was not detected in nasopaheryngeal carcinoma (NPC) cell line, C666.1,-derived exosomes. In contrast, EBV-associated RNAs, such as EBERs and BART-miRNAs, was easily detected in the exosomes. One of BART-miRNAs, miR-BART17-5p, was secreted in extra-ordinally pathway, but in exsosome-independent pathway. The miRNA would be expected as novel therapeutic target of NPC.
|